Sign in
Taking peoplePhase 4

EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics

Key facts

Who runs it
National University of Singapore
Where
Greece, India, Italy, Malaysia, Singapore, South Korea, Taiwan, Thailand, and Türkiye27 sites in 9 countriesChoose a country to see its sites
Status
Recruiting
Phase
Phase 4
People taking part
1,526 people, planned
Started
12 Dec 2023
Expected to end
31 Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Rapid Diagnostics
Record updated
22 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Adult patients aged 18 years or older (21 years or older in Singapore) who meet at least one of the following criteria:; At risk of developing bloodstream infection, hospital-acquired pneumonia (HAP), or ventilator-associated pneumonia (VAP) due to Pseudomonas aeruginosa or carbapenem-resistant Enterobacterales; OR; Blood culture bottles showing Gram-negative bacilli on Gram stain; OR; Suspected HAP or VAP with respiratory specimens showing Gram-negative bacteria on Gram stain
  • For randomisation, all of the following criteria must be fulfilled:; Written informed consent obtained from the participant or their authorised representative; An appropriate blood or respiratory specimen received by the participating microbiology laboratory, with Gram-negative bacilli detected on Gram stain; Patients with HAP or VAP must fulfil the US Centers for Disease Control and Prevention National Healthcare Safety Network (CDC NHSN) criteria; No exclusion criteria are met

Who cannot take part

  • Previous enrolment in the RAPID trial within the preceding 60 days
  • Refractory shock or comorbid condition such that the patient is not expected to survive more than 48 hours
  • Suspected catheter-related bloodstream infection where the implicated vascular catheter cannot be removed
  • Treatment is not intended to cure the infection
  • Infection requiring prolonged antibiotic treatment (more than two weeks)
  • Patients younger than 18 years (younger than 21 years in Singapore)
  • Incarceration in a correctional facility

This trial has no sites in United States.

It has sites in 9 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

RAPID is an investigator initiated Phase 4, multinational, multicentre, open-label, randomised controlled superiority trial evaluating the clinical impact of rapid microbiological diagnostics combined with antimicrobial stewardship and early targeted antibiotic therapy compared with standard-of-care diagnostics and antibiotics.

Read full original descriptionShow less

Hospitalised adult patients with bloodstream infections, hospital-acquired pneumonia or ventilator-associated pneumonia are randomised in a 1:1 ratio to the intervention or control arm.

The main analysis population comprises patients with infections caused by Pseudomonas aeruginosa or carbapenem-resistant Enterobacterales. A secondary analysis population includes patients with infections caused by other specified multidrug-resistant Gram-negative organisms.

Patients will be randomised to either a control or intervention arm. Patients randomised to the intervention arm will have relevant specimens analysed by rapid microbiological diagnostics and will have early availability of ceftazidime-avibactam if appropriate. Patients randomised to the control arm, will have samples analysed by clinical microbiology laboratories using standard of care diagnostics. Antibiotics will be available to these patients as per usual institutional practice.

The primary outcome is a composite of all-cause mortality or absence of improvement in Sequential Organ Failure Assessment (SOFA) score at Day 14 following the index culture.

The 2 groups in the trial

  • InterventionExisting treatment, for comparison

    Rapid microbiological diagnostics using the BioFire BCID2 Panel for bloodstream infections or BioFire FilmArray Pneumonia/Pneumonia Plus Panel for respiratory infections, combined with locally adapted antimicrobial stewardship and early targeted antibiotic therapy. Samples from patients randomised to the intervention arm will undergo the BioFire FilmArray systems. Patients will be then administered with the study drug, ceftazidime-avibactam when Pseudomonas aeruginosa or carbapenemase producing Enterobacterales detected. Appropriate antibiotic must be administered according to predefined antibiotic stewardship guidelines within 24 hours of the Gram stain being performed on the index specimen.

    Treatment: Rapid Diagnostics

  • ControlNo study treatment, for comparison

    Standard-of-care microbiological diagnostics and antibiotic treatment according to local clinical practice and treating physician discretion. Patients randomised to the control arm, will have samples analysed by clinical microbiology laboratories using standard of care diagnostics. Antibiotics treatment will be administered as per usual institutional practice from hospital supplies.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics Versus Standard of Care Antibiotics and Diagnostics in Patients With Bloodstream Infection, Hospital-acquired Pneumonia or Ventilator-associated Pneumonia Due to Pseudomonas Aeruginosa or Carbapenemase Producing Enterobacterales (RAPID)
Record updated
22 October 2026